19 results on '"Reed N."'
Search Results
2. Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy
- Author
-
Despierre, Evelyn, Vergote, Ignace, Anderson, Ryan, Coens, Corneel, Katsaros, Dionyssios, Hirsch, Fred R., Boeckx, Bram, Varella Garcia, Marileila, Ferrero, Annamaria, Ray Coquard, Isabelle, Berns, Els M. J. J., Casado, Antonio, Lambrechts, Diether, Jimeno, Antonio, Abraham, C, Chesnay, L, Amant, F, Anderson, R, Azzedine, A, Benedetto, Chiara, Bertelli, G, Berteloot, P, Berton Rigaud, D, Biglia, N, Bonichon Lamichhane, N, Bougnoux, P, Bourbouloux, E, Bourcier, C, Buck, M, Campone, M, Canuto, Em, Casado Herraez, A, Cauvin, I, Chauvenet, L, Chevalier Place, A, Cottu, P., Cretin, J, Cumin, I, Curé, H, Dalenc, F, Danese, S, Davis, A, Debruyne, P, Delplanque, G, Delva, R, D'Hondt, V, Dramais, D, Durando, X, El Kouri, C, Esteban, C, Fabbro, M, Falandry, C, Filleul, B, Floquet, A, Fumoleau, P, Garcia Varella, M, Garnier, C, Gilby, E, Gladieff, L, Goffin, F, Gouttebel, M., Green, Ja, Guastalla, J., Hardy Bessard, A., Hirsch, F, Hughes, A, Jaubert, D, Kaminsky, M., Katsaros, D, Largillier, R, Lebrun Jezekova, D, Leduc, B, Leheurteur, M, Lesoin, A, Leunen, K, Levasseur, N, Leyronnas, C, Llory, J., Lortholary, A, Mayer, F, Mayeur, D, Mendiola, C, Mignot, L, Morgan, J, Mouret Reynier, M., Neven, P, Petit, T, Picardo, E, Plaza, J, Pluvio Coronado, M, Priou, F, Pujade Lauraine, E, Coquard, I, Reed, N, Rigault de la Longrais, I, Scholl, S, Sillet Bach, I, Steer, C, Summers, J, Trillet Lenoir, V, Van Dam, P, Van Der Burg ME, Vanlerenberghe, E, Vannetzel, J., Vergote, I, Aragon, Ja, Waters, J, Weber, B, Yazbek, G, Zola, P., Medical Oncology, and Other departments
- Subjects
Neuroblastoma RAS viral oncogene homolog ,Oncology ,Adult ,Cancer Research ,medicine.medical_specialty ,Organoplatinum Compounds ,medicine.disease_cause ,Article ,Aged ,Aged, 80 and over ,Antineoplastic Combined Chemotherapy Protocols ,Biomarkers, Tumor ,Disease Progression ,Disease-Free Survival ,Erlotinib Hydrochloride ,Female ,Humans ,Middle Aged ,Mutation ,Ovarian Neoplasms ,Protein Kinase Inhibitors ,Protein Kinases ,Receptor, Epidermal Growth Factor ,Pharmacology (medical) ,SDG 3 - Good Health and Well-being ,Internal medicine ,80 and over ,Medicine ,EGFR Gene Amplification ,Epidermal growth factor receptor ,neoplasms ,Tumor ,Epidermal Growth Factor ,biology ,business.industry ,Cancer ,medicine.disease ,ErbB Receptors ,biology.protein ,Biomarker (medicine) ,Erlotinib ,KRAS ,business ,Ovarian cancer ,Biomarkers ,Receptor ,medicine.drug - Abstract
In this work, we aimed to identify molecular epidermal growth factor receptor (EGFR) tissue biomarkers in patients with ovarian cancer who were treated within the phase III randomized European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG) 55041 study comparing erlotinib with observation in patients with no evidence of disease progression after first-line platinum-based chemotherapy. Somatic mutations in KRAS, BRAF, NRAS, PIK3CA, EGFR, and PTEN were determined in 318 (38 %) and expression of EGFR, pAkt, pMAPK, E-cadherin and Vimentin, and EGFR and HER2 gene copy numbers in 218 (26 %) of a total of 835 randomized patients. Biomarker data were correlated with progression-free survival (PFS) and overall survival (OS). Only 28 mutations were observed among KRAS, BRAF, NRAS, PIK3CA, EGFR, and PTEN (in 7.5 % of patients), of which the most frequent were in KRAS and PIK3CA. EGFR mutations occurred in only three patients. When all mutations were pooled, patients with at least one mutation in KRAS, NRAS, BRAF, PIK3CA, or EGFR had longer PFS (33.1 versus 12.3 months; HR 0.57; 95 % CI 0.33 to 0.99; P = 0.042) compared to those with wild-type tumors. EGFR overexpression was detected in 93 of 218 patients (42.7 %), and 66 of 180 patients (36.7 %) had EGFR gene amplification or high levels of copy number gain. Fifty-eight of 128 patients had positive pMAPK expression (45.3 %), which was associated with inferior OS (38.9 versus 67.0 months; HR 1.81; 95 % CI 1.11 to 2.97; P = 0.016). Patients with positive EGFR fluorescence in situ hybridization (FISH) status had worse OS (46.1 months) than those with negative status (67.0 months; HR 1.56; 95 % CI 1.01 to 2.40; P = 0.044) and shorter PFS (9.6 versus 16.1 months; HR 1.57; 95 % CI 1.11 to 2.22; P = 0.010). None of the investigated biomarkers correlated with responsiveness to erlotinib. In this phase III study, increased EGFR gene copy number was associated with worse OS and PFS in patients with ovarian cancer. It remains to be determined whether this association is purely prognostic or is also predictive.
- Published
- 2015
3. Cancer Antigen 125: Lost to Follow-Up?
- Author
-
Verheijen, R. H., Cibula, D., Zola, P., Reed, N., council of the European Society of Gynaecologic Oncology, and Kimmig, Rainer (Beitragende*r)
- Subjects
Oncology ,medicine.medical_specialty ,Chemotherapy ,business.industry ,medicine.medical_treatment ,Gynaecological oncology ,Medizin ,Obstetrics and Gynecology ,medicine.disease ,Cancer antigen ,Serous fluid ,Quality of life ,Internal medicine ,Medicine ,Lost to follow-up ,business ,Intensive care medicine ,Ovarian cancer ,Tumor marker - Abstract
A recent study on the use of cancer antigen 125 (CA-125) in follow-up of patients with epithelial ovarian cancer after complete response on primary treatment is critically reviewed. As it has been suggested to refrain from CA-125 altogether, this European Society of Gynaecologic Oncology report has also reviewed possible disadvantages, even possible harm, and potentially missed opportunities when such policy would be implemented. It is concluded that indeed routine use of CA-125 does not provide patient benefit in survival or quality of life. However, there may be other reasons for monitoring CA-125, which are discussed in this review. It is noted that the lack of benefit of CA-125 monitoring has only been proven for a specific subset of ovarian cancer patients with serous histology and frequent follow-up visits including imaging and in a clinical environment where, particularly, surgery for recurrent disease and clinical studies on new second-line agents will not be considered. A special warning is issued not to stop tumor marker follow-up in other than epithelial ovarian cancers and in follow-up of patients who not have been treated with chemotherapy.
- Published
- 2012
4. Routine germline BRCA1 and BRCA2 testing in patients with ovarian carcinoma: analysis of the Scottish real-life experience.
- Author
-
Rust, K., Spiliopoulou, P., Tang, C. Y., Bell, C., Stirling, D., Phang, T. H. F., Davidson, R., Mackean, M., Nussey, F., Glasspool, R. M., Reed, N. S., Sadozye, A., Porteous, M., McGoldrick, T., Ferguson, M., Miedzybrodzka, Z., McNeish, I. A., Gourley, C., and Phang, Thf
- Subjects
BRCA genes ,OVARIAN cancer ,GERM cells ,TUMOR suppressor genes ,CANCER genetics ,EPIDEMIOLOGY of cancer ,CANCER ,COMPARATIVE studies ,DISEASE susceptibility ,RESEARCH methodology ,MEDICAL cooperation ,GENETIC mutation ,OVARIAN tumors ,PROTEINS ,RESEARCH ,RESEARCH funding ,GENETIC testing ,EVALUATION research ,DISEASE prevalence ,RETROSPECTIVE studies - Abstract
Objective: To determine the rates of germline BRCA1 and BRCA2 mutations in Scottish patients with ovarian cancer, before and after a change in testing policy.Design: Retrospective cohort study.Setting: Four cancer/genetics centres in Scotland.Population: Patients with ovarian cancer undergoing germline BRCA1 and BRCA2 (gBRCA1/2) sequencing before 2013 (under the 'old criteria', with selection based solely on family history), after 2013 (under the 'new criteria', with sequencing offered to newly presenting patients with non-mucinous ovarian cancer), and in the 'prevalent population' (who presented before 2013, but were not eligible for sequencing under the old criteria but were sequenced under the new criteria).Methods: Clinicopathological and sequence data were collected before and for 18 months after this change in selection criteria.Main Outcome Measures: Frequency of germline BRCA1, BRCA2, RAD51C, and RAD51D mutations.Results: Of 599 patients sequenced, 205, 236, and 158 were in the 'old criteria', 'new criteria', and 'prevalent' populations, respectively. The frequency of gBRCA1/2 mutations was 30.7, 13.1, and 12.7%, respectively. The annual rate of gBRCA1/2 mutation detection was 4.2 before and 20.7 after the policy change. A total of 48% (15/31) 'new criteria' patients with gBRCA1/2 mutations had a Manchester score of <15 and would not have been offered sequencing based on family history criteria. In addition, 20 patients with gBRCA1/2 were identified in the prevalent population. The prevalence of gBRCA1/2 mutations in patients aged >70 years was 8.2%.Conclusions: Sequencing all patients with non-mucinous ovarian cancer gives a much higher annual gBRCA1/2 mutation detection rate, with the frequency of positive tests still exceeding the 10% threshold upon which many family history-based models operate.Tweetable Abstract: BRCA sequencing all non-mucinous cancer patients increases mutation detection five fold. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
5. A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer.
- Author
-
Rustin, G., Reed, N., Jayson, G. C., Ledermann, J. A., Adams, M., Perren, T., Poole, C., Lind, M., Persic, M., Essapen, S., Gore, M., Calvert, H., Stredder, C., Wagner, A., Giurescu, M., and Kaye, S.
- Subjects
- *
ANTINEOPLASTIC agents , *OVARIAN cancer , *PLATINUM , *CANCER relapse , *DRUG tolerance , *NEUROPATHY , *RANDOMIZED controlled trials - Abstract
Background: Sagopilone, the first fully synthetic epothilone, has shown promising preclinical activity in tumour models. This open-label randomised phase II study investigated two infusion schedules of sagopilone in women with ovarian cancer.Patients and methods: Women with ovarian cancer recurring within 6 months of end of last platinum-containing treatment received sagopilone 16 mg/m2 as a 3- or 0.5-h i.v. infusion every 21 days for up to 6 weeks.Results: Sixty-three patients received sagopilone as a 3-h (n = 38) or 0.5-h (n = 25) infusion. There were nine confirmed tumour responses [by modified RECIST (n = 8) and by Gynecologic Cancer Intergroup CA-125 criteria (n = 1)] in 57 patients assessable for efficacy overall [three (13%) with 0.5-h and six (18%) with 3-h infusions]. The 0.5-h arm was closed when it failed to meet its target efficacy. Main drug-related adverse events were peripheral sensory neuropathy (73%; 16% grade 3), nausea (37%; 2% grade 3), fatigue (35%; 3% grade 3) and arthralgia (30%; 5% grade 3). Overall incidence of peripheral sensory neuropathy was similar in both treatment arms, with no grade 4 neuropathy events. No acute allergic infusion reactions were observed.Conclusion: Sagopilone is effective, with balanced tolerability, in patients with recurrent platinum-resistant ovarian cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
6. Experience of Weekly Carboplatin and Paclitaxel in Treatment Resistant Ovarian Cancer.
- Author
-
Roxburgh, Patricia, Reed, N., and Glasspool, R. M.
- Subjects
- *
PACLITAXEL , *OVARIAN cancer treatment , *DRUG resistance in cancer cells , *DRUG therapy , *RETROSPECTIVE studies , *NEUTROPENIA , *THROMBOCYTOPENIA - Abstract
OBJECTIVE To investigate tolerability and efficacy of weekly carboplatin and paclitaxel in treatment resistant epithelial ovarian cancer (EOC). DESIGN Retrospective case note review. SETTING The Beatson West of Scotland Cancer Centre. POPULATION Patients with EOC, fallopian tube, or primary peritoneal cancer progressing on or recurring within 6 months of their last treatment who received weekly carboplatin and paclitaxel. METHODS Chemotherapy records of the patients described above were retrospectively reviewed. MAIN OUTCOME MEASURES Dose delay, dose reduction, dose intensity, toxicity, response rate, progression free survival, and overall survival. RESULTS Forty-two patients were identified. Thirteen patients were treated with carboplatin and paclitaxel, given once per week for 3 weeks followed by a week off. Twenty-nine patients were treated on a continuous weekly basis. Mean dose intensity was 80>91% for carboplatin and 79>87% for paclitaxel. Of 38 assessable patients, grade three or four neutropenia affected 15 patients, anemia and thrombocytopenia affected five, and there were two cases of neutropenic sepsis. Nonhematological toxicity included lethargy and alopecia. Overall response rate by CA125 or CT was 54% (7/13) for the 3 weeks out of 4 regimen and 45% (13/29) for the continuous regimen. Median overall and progression free survivals were 22 and 17 weeks, respectively, for the 3 out of 4 week regimen and 18 and 7 weeks with the continuous schedule. CONCLUSION Weekly treatment with carboplatin and paclitaxel is feasible, reasonably well tolerated, and active in heavily pretreated patients with treatment-resistant EOC. [ABSTRACT FROM AUTHOR]
- Published
- 2011
7. Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer.
- Author
-
Lee, C. K., Gurney, H., Brown, C., Sorio, R., Donadello, N., Tulunay, G., Meier, W., Bacon, M., Maenpaa, J., Petru, E., Reed, N., Gebski, V., Pujade-Lauraine, E., Lord, S., Simes, R. J., and Friedlander, M.
- Subjects
LEUCOCYTES ,OVARIAN cancer ,CANCER chemotherapy ,SENSORY neurons ,GLOMERULAR filtration rate ,PHYSIOLOGY - Abstract
Background: We assess the prognostic value of chemotherapy-induced leukopenia and sensory neuropathy in the CALYPSO trial patients treated with carboplatin-paclitaxel (CP) or carboplatin-liposomal doxorubicin (CPLD).Methods: We performed a landmark analysis at first month after randomisation to correlate leukopenia (nadir white blood cell <4.0 × 10(9) per litre or severe infection) during cycle 1 of chemotherapy with progression-free survival (PFS). Using time-dependent proportional-hazards models, we also investigated the association between neuropathy and PFS.Results: Of 608 patients with nadir blood and did not receive growth factors, 72% (CP=70%, CPLD=73%) had leukopenia. Leukopenia was prognostic for PFS in those receiving CP (adjusted hazard ratio (aHR) 0.66, P=0.01). Carboplatin-liposomal doxorubicin was more effective than CP in patients without leukopenia (aHR 0.51, P=0.001), but not those experiencing leukopenia (aHR 0.93, P=0.54; interaction P=0.008).Of 949 patients, 32% (CP=62%, CPLD=28%) reported neuropathy during landmark. Neuropathy was prognostic for PFS in the CP group only (aHR 0.77, P=0.02). Carboplatin-liposomal doxorubicin appeared to be more effective than CP among patients without neuropathy (aHR 0.70, P<0.0001), but not those with neuropathy (aHR 0.96, P=0.81; interaction P=0.15).Conclusion: First-cycle leukopenia and neuropathy were prognostic for patients treated with CP. Efficacy of CP treatment was similar to CPLD in patients who developed leukopenia. These findings support further research to understand the mechanisms of treatment-related toxicity. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
8. SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer.
- Author
-
Vasey, P. A., Atkinson, R., Osborne, R., Parkin, D., Symonds, R., Paul, J., Lewsley, L., Coleman, R., Reed, N. S., Kaye, S., and Rustin, G. J. S.
- Subjects
DOCETAXEL ,DRUG therapy ,CANCER patients ,ALKALOIDS ,THERAPEUTICS - Abstract
The feasibility of sequential carboplatin followed by docetaxel-based therapy for untreated ovarian cancer was determined. Patients received four q3w cycles of carboplatin AUC 7, then four q3w cycles of either docetaxel 100 mg m(-2) (day 1) (arm A); docetaxel 75 mg m(-2) (day 8) and gemcitabine 1250 mg m(-2) (days 1,8) (arm B) or docetaxel 25 mg m(-2) and gemcitabine 800 mg m(-2) (both given weekly (days 1,8,15)) (arm C). A total of 44 patients were randomised to each treatment arm. None of the arms demonstrated an eight cycle completion rate (70.5/72.7/45.5% in arms A/B/C, respectively), which was statistically greater than 60% (P=0.102, P=0.056, P=0.982) which was our formal feasibility criteria, although only the completion rate in arm C was clearly worse than this level. The overall response rate (ORR) after carboplatin was 65.7% in 70 evaluable patients. In evaluable patients, ORRs after docetaxel-based cycles were: arm A 84.0% (21 out of 25); arm B 77.3% (17 out of 22); arm C 69.6% (16 out of 23). At follow-up (median 30 months), median progression-free survival times were: arm A 15.5 months (95% CI: 10.5-20.6); arm B 18.1 months (95% CI: 15.9-20.3); arm C, 13.7 months (95% CI: 12.8-14.6). Neutropenia was the predominant grade 3-4 haematological toxicity: 77.8/85.7/54.4% in arms A/B/C, respectively. Dyspnoea was markedly increased in both gemcitabine-containing arms (P=0.001) but was worse in arm C. Although just failing to rule out eight cycle completion rates less than 60%, within the statistical limitations of these small cohorts, the overall results for arms A and B are encouraging. Larger phase III studies are required to test these combinations. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
9. A phase II trial of capecitabine (Xeloda) in recurrent ovarian cancer.
- Author
-
Vasey, P. A., McMahon, L., Paul, J., Reed, N., and Kaye, S. B.
- Subjects
OVARIAN cancer ,DRUG side effects ,CANCER treatment ,MEDICAL research - Abstract
Oral capecitabine is a highly active, well-tolerated and convenient treatment for breast and colorectal cancer. This trial assessed the efficacy and safety of single-agent capecitabine in patients with previously treated ovarian cancer. A total of 29 patients with platinum-pretreated relapsed ovarian cancer were enrolled in this prospective, open-label, single-centre, phase II study. Patients received oral capecitabine 1250 mg m(-2) twice daily on days 1-14 of a 21-day cycle. Tumour response was evaluated using serum CA125. Out of 29 enrolled patients, 28 were evaluable, and a response was observed in eight patients (29%, 95% confidence interval (CI), 13-49%). Median progression-free and overall survivals were 3.7 (95% CI, 2.8-4.6) and 8.0 (95% CI, 4.1-11.8) months, respectively. After 6 months of treatment, 28% (95% CI, 13-48%) of patients remained progression-free and 62% (95% CI, 42-79%) were still alive. The most common clinical adverse events were hand-foot syndrome (HFS), nausea and diarrhoea. Grade 3 HFS occurred in 14% of patients, grade 3 vomiting in 10%. Efficacy and safety of capecitabine compare favourably with other monotherapies in platinum-refractory epithelial ovarian cancer. The convenience and improved safety profile of capecitabine compared with intravenous. regimens make it an ideal agent for administration in the outpatient setting. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
10. A phase II trial of capecitabine (Xeloda®) in recurrent ovarian cancer.
- Author
-
Vasey, P. A., McMahon, L., Reed, N., Kay, S. B., and Miller, Brigitte E.
- Subjects
OVARIAN cancer ,ONCOLOGY research ,EPITHELIAL cells ,CANCER relapse ,DRUG therapy ,PALLIATIVE treatment ,ORAL medicine - Abstract
Details a gynecologic oncology phase II trial of capecitabine in recurrent epithelial ovarian cancer. Impact of the increase in chemotherapeutic options on patients with recurrent ovarian cancer; Major consideration during a palliative treatment; Examples of oral agents and their effectiveness.
- Published
- 2004
- Full Text
- View/download PDF
11. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
- Author
-
Reed, N., Millan, D., Verheijen, R., and Castiglione, M.
- Subjects
- *
OVARIAN cancer , *CANCER in women , *CANCER diagnosis , *GERM cell tumors , *TOMOGRAPHY , *MAGNETIC resonance imaging , *CANCER treatment - Abstract
The article focuses on the clinical practice guidelines for the diagnosis, treatment and reexamination of patients with non-epithelial ovarian cancer. It says that computed tomography (CT) and magnetic resonance imaging (MRI) are used to assist the staging and planning surgery. It mentions that symptoms of a pelvic mass and suspicions of germ cell tumour (GCT) should be considered in the diagnosis of non-epithelial ovarian cancer for younger women. Moreover, 5 years of follow-up is recommended.
- Published
- 2010
- Full Text
- View/download PDF
12. Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.
- Author
-
Zweifel, M., Jayson, G. C., Reed, N. S., Osborne, R., Hassan, B., Ledermann, J., Shreeves, G., Poupard, L., Lu, S.-P., Balkissoon, J., Chaplin, D. J., and Rustin, G. J. S.
- Subjects
- *
OVARIAN cancer , *PHOSPHATES , *PACLITAXEL , *NEUTROPENIA , *THROMBOCYTOPENIA , *NEUROPATHY , *NITROGLYCERIN - Abstract
Background: A previous dose-escalation trial of the vascular disrupting agent combretastatin A4 phosphate (CA4P) given before carboplatin, paclitaxel, or both showed responses in 7 of 18 patients with relapsed ovarian cancer.Patients and methods: Patients with ovarian cancer that had relapsed and who could start trial therapy within 6 months of their last platinum chemotherapy were given CA4P 63 mg/m2 minimum 18 h before paclitaxel 175 mg/m2 and carboplatin AUC (area under the concentration curve) 5, repeated every 3 weeks.Results: Five of the first 18 patients’ disease responded, so the study was extended and closed after 44 patients were recruited. Grade ≥2 toxic effects were neutropenia in 75% and thrombocytopenia in 9% of patients (weekly blood counts), tumour pain, fatigue, and neuropathy, with one patient with rapidly reversible ataxia. Hypertension (23% of patients) was controlled by glyceryl trinitrate or prophylactic amlodipine. The response rate by RECIST was 13.5% and by Gynecologic Cancer InterGroup CA 125 criteria 34%.Conclusions: The addition of CA4P to paclitaxel and carboplatin is well tolerated and appears to produce a higher response rate in this patient population than if the chemotherapy was given without CA4P. A planned randomised trial will test this hypothesis. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
13. A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer.
- Author
-
Rustin, G., Vergote, I., Micha, J.P., Duska, L.R., Reed, N., Bendell, J., Spitz, D., Dark, G., Hoch, U., Tagliaferri, M., Hannah, A.L., and Garcia, A.A.
- Subjects
- *
OVARIAN cancer treatment , *CANCER relapse , *IRINOTECAN , *CANCER in women , *PRIMARY care - Abstract
Objective Etirinotecan pegol (EP) is a novel polyethylene glycol conjugated form of irinotecan with documented activity in platinum-resistant ovarian cancer (PROC). We report the results of the expanded portion of a phase II study of EP in patients with PROC who received prior pegylated liposomal doxorubicin (PLD) or who were unable to receive it. Methods This multicenter, open-label, phase II study evaluated EP q21d for PROC. The primary endpoint was objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors version 1.0. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety. Patient populations evaluated included a modified intent-to-treat (mITT) group consisting of all patients who received at least one dose and with measurable disease and a primary efficacy (pEFF) group (subset of the mITT population who received prior PLD). Results One hundred thirty-nine patients were enrolled. Of the 132 patients in the mITT group, 20 achieved an ORR (15.2%; 95% CI 9.5–22.4); median PFS and OS were 4.4 months and 10.2 months, respectively. In the pEFF group (n = 104), 15 patients (14.4%; 95% CI 8.3–22.7) achieved an ORR; median PFS and OS were 4.4 months and 10.9 months, respectively. The most common grade 3/4 toxicities were diarrhea (20%), abdominal pain (17%), vomiting (14%), dehydration (13%), and nausea (13%). Severe diarrhea was reduced to 15% with strict adherence to screening and management guidelines. Conclusions This study confirms the activity and safety of single-agent EP in patients with PROC, including patients who received prior PLD. Further evaluation earlier in the disease course and in combination is warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
14. Health-related quality of life in recurrent platinum-sensitive ovarian cancer—results from the CALYPSO trial.
- Author
-
Brundage, M., Gropp, M., Mefti, F., Mann, K., Lund, B., Gebski, V., Wolfram, G., Reed, N., Pignata, S., Ferrero, A., Brown, C., Eisenhauer, E., and Pujade-Lauraine, E.
- Subjects
- *
QUALITY of life , *OVARIAN cancer , *CLINICAL trials , *PLATINUM , *CARBOPLATIN , *PACLITAXEL , *CANCER relapse - Abstract
Background In the CALYPSO trial, carboplatin–pegylated liposomal doxorubicin (CD) demonstrated superior therapeutic index versus carboplatin–paclitaxel (CP) in patients with recurrent ovarian cancer. This paper reports the health-related quality of life (HRQoL) findings. Materials and methods HRQoL was measured with the EORTC QoL-QC30 questionnaire and OV28 ovarian cancer module. Mean change scores from baseline in HRQoL subscales (five functional scales and global health status) in each arm and the proportion of patients improved or worsened were calculated every 3 months until 12 months. Results Compliance was 90% at baseline and 76%, 64%, 57% at 3, 6, and 9 months, respectively. Baseline HRQoL showed already impaired global scores (mean 62/100) and considerable symptom burden (90% of patients reporting nonzero scores). Global QoL and abdominal symptom scores improved over time in both arms; at 6 months, 36% of patients met criteria for improved symptoms. Treatment with CD resulted in less peripheral neuropathy (9.8 versus 24.2), fewer other chemotherapy side-effects (9.5 versus 16.2), and less impact on body image (3.8 versus 10.4) versus CP (all P < 0.02) at 6 months. Conclusions These patient-reported outcomes confirm the overall lower toxicity of CD versus CP. The improved disease-related outcomes achieved with CD were not at the expense of QoL. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
15. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.
- Author
-
Gladieff, L., Ferrero, A., De Rauglaudre, G., Brown, C., Vasey, P., Reinthaller, A., Pujade-Lauraine, E., Reed, N., Lorusso, D., Siena, S., Helland, H., Elit, L., and Mahner, S.
- Subjects
- *
CARBOPLATIN , *DOXORUBICIN , *PACLITAXEL , *OVARIAN cancer treatment , *ANTINEOPLASTIC agents , *CLINICAL trials , *LIPOSOMES - Abstract
Background: To perform a subset analysis of patients with partially platinum-sensitive recurrent ovarian cancer (ROC) who received either CD [carboplatin–pegylated liposomal doxorubicin (PLD)] or CP (carboplatin–paclitaxel) in the CALYPSO trial. Patients and methods: CALYPSO, an international phase III, non-inferiority trial, enrolled women with ROC that relapsed >6 months following first- or second-line therapy. Patients were randomized to CD or CP. Patients with a treatment-free interval of >6 and ≤12 months were evaluated for progression-free survival (PFS), the primary end point of CALYPSO trial, and safety. Results: A total of 344 partially platinum-sensitive patients were included (N = 161, CD and N = 183, CP). The hazard ratio for PFS was 0.73 (95% confidence interval: 0.58–0.90; P = 0.004 for superiority) in favor of CD. Median PFS times were 9.4 months (CD) and 8.8 months (CP). Toxicities more common with CP versus CD included grade 3/4 neutropenia (50% versus 39%; P = 0.015), grade 2 alopecia (86% versus 9%; P < 0.001), neuropathy and hypersensitivity reactions. Hand-foot syndrome was more common with CD; however, grade 3/4 reactions were low (one patient in each arm). Conclusion: Carboplatin–PLD has a more favorable risk-benefit profile than CP in patients with partially platinum-sensitive ROC and should be considered an effective treatment option for these patients. [ABSTRACT FROM PUBLISHER]
- Published
- 2012
- Full Text
- View/download PDF
16. Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study.
- Author
-
Kurtz, J. E., Kaminsky, M. C., Floquet, A., Veillard, A. S., Kimmig, R., Dorum, A., Elit, L., Buck, M., Petru, E., Reed, N., Scambia, G., Varsellona, N., Brown, C., and Pujade-Lauraine, E.
- Subjects
- *
OVARIAN cancer , *DISEASES in older people , *CANCER chemotherapy , *PACLITAXEL , *CANCER relapse , *DOXORUBICIN , *HEALTH outcome assessment - Abstract
Background: CALYPSO (CAeLYx in Platinum Sensitive Ovarian) patients compared carboplatin–pegylated liposomal doxorubicin (C–PLD) with carboplatin–paclitaxel (C–P) in patients with late-relapsing recurrent ovarian cancer (ROC). We analyzed outcomes in patients ≥70 years.Patients and methods: Nine hundred and seventy-six patients with taxane-pretreated ROC relapsing >6 months after first- or second-line platinum-based therapy were randomly assigned to 4-weekly C area under the curve (AUC) 5 plus PLD 30 mg/m2 or 3-weekly C AUC 5 plus P 175 mg/m2 for six or more cycles.Results: One hundred and fifty-seven (16%) patients ≥70 years (median: 74 years, C–PLD; 73 years, C–P; range 70–82 years) were included (n = 71, C–PLD; n = 86, C–P). In comparing elderly and younger, elderly patients experienced fewer grade ≥2 allergic reactions (P = 0.005) but more grade ≥2 sensory neuropathy (P = 0.007). Myelosuppression did not differ with age. Elderly patients completed planned treatment as frequently as younger (79%, C–PLD; 82%, C–P). In comparing arms within elderly patients, C–P was associated with more grade ≥2 alopecia, sensory neuropathy, arthralgia/myalgia (P < 0.001 for all), severe leukopenia plus febrile neutropenia; C–PLD was associated with more grade ≥2 hand–foot syndrome (P = 0.005). Median progression-free survival was 11.6 months (C–PLD) and 10.3 months (C–P; P = 0.44).Conclusions: Patients ≥70 years experienced more neuropathy, with a higher incidence in the C–P arm. Similar to all study patients, C–PLD provided a better therapeutic index with less toxicity than C–P in elderly women with platinum-sensitive ROC. [ABSTRACT FROM AUTHOR]
- Published
- 2011
17. Follow-up in gynecological malignancies: A state of art
- Author
-
Nicholas Reed, C Macchi, T Maggino, Rainer Kimmig, Nicoletta Colombo, Vesna Kesic, David Cibula, Paolo Zola, Zola, P, Macchi, C, Cibula, D, Colombo, N, Kimmig, R, Maggino, T, Reed, N, and Kesic, V
- Subjects
medicine.medical_specialty ,Genital Neoplasms, Female ,Cost-Benefit Analysis ,MEDLINE ,Medizin ,Obstetrics and gynaecology ,Quality of life ,Endometrial cancer ,Ovarian cancer ,medicine ,Humans ,Cervical cancer ,Follow-up ,State of art ,Obstetrics and Gynecology ,Oncology ,Practice Patterns, Physicians' ,Intensive care medicine ,Prospective cohort study ,Evidence-Based Medicine ,business.industry ,Obstetrics ,Retrospective cohort study ,Evidence-based medicine ,medicine.disease ,Quality of Life ,Female ,business ,Follow-Up Studies - Abstract
ObjectiveThe main purpose of this article is to explore the current practice for follow-up of gynecological cancer, pointing out the different procedures, to determine the most clinically and cost-effective surveillance strategies after the primary treatment.Materials and MethodsWe analyzed the follow up strategies for ovarian, endometrial, and cervical cancer. All of the topics discussed below arose from the “ESGO State of Art Conference—Follow-up in gynaecological malignancies” in Turin, (September 11–13, 2014;http://torino2014.esgo.org/).ResultsPhysical but these practices should be integrated with biomarkers or imaging strategies. Currently, most recommendations about follow-up are based on retrospective studies and expert opinion, and there is some disagreement on surveillance strategies due to lack of evidence-based knowledge.ConclusionsAll surveillance procedures should be evidence-based with a clearly defined purpose: there is a need for prospective studies to compare the effectiveness of different follow-up regimens measuring overall survival, detection of recurrence, quality of life (QoL), and costs as outcomes.
- Published
- 2015
18. Recommendations of the Fertility Task Force of the European Society of Gynecologic Oncology about the conservative management of ovarian malignant tumors
- Author
-
Alex Rodolakis, Nicoletta Colombo, Dominik Denschlag, Philippe Morice, Achim Schneider, Nicholas S. Reed, Vesna Kesic, Morice, P, Denschlag, D, Rodolakis, A, Reed, N, Schneider, A, Kesic, V, and Colombo, N
- Subjects
Oncology ,Infertility ,medicine.medical_specialty ,endocrine system diseases ,MED/40 - GINECOLOGIA E OSTETRICIA ,media_common.quotation_subject ,Advisory Committees ,Fertility ,Gynecologic oncology ,Medical Oncology ,Ovarian tumor ,Internal medicine ,medicine ,Humans ,Neoplasms, Glandular and Epithelial ,Stage (cooking) ,media_common ,Advisory Committee ,Ovarian Neoplasms ,Endometrioid tumor ,business.industry ,Ovarian Neoplasm ,Obstetrics and Gynecology ,medicine.disease ,Europe ,Serous fluid ,Gynecology ,Practice Guidelines as Topic ,Female ,Ovarian cancer ,business ,Infertility, Female - Abstract
In young patients with borderline ovarian tumor a conservative treatment approach does not seem to have a significant impact on survival, and the outcome regarding fertility is good in general. It can be considered even if noninvasive peritoneal implants are discovered at the time of the initial surgery. In contrast, in patients with epithelial ovarian cancer, conservative surgery should be considered only in adequately staged patients, with a stage IA grade 1 (and probably 2) serous, mucinous or an endometrioid tumor, including a careful follow-up. Such an approach could also probably be discussed in stage IC grade 1 disease. In patients with nonepithelial malignant ovarian tumors, conservative surgery is also feasible, particularly in patients with malignant germ cell tumors because of their high chemosensitivity leading to an excellent prognosis in general. Copyright © 2011 by IGCS and ESGO.
- Published
- 2011
19. First-line therapy in ovarian cancer trials
- Author
-
Maurie Markman, Dolores Gallardo, Monica Bacon, Larry Rubinstein, Gunnar B. Kristensen, Henry C Kitchener, Nicholas S. Reed, Michael A. Quinn, Gavin Stuart, Andreas duBois, Jonathan S. Berek, Jacobus Pfisterer, William J. Hoskins, Nicoletta Colombo, Marie Plante, Philip J. DiSaia, Tate Thigpen, Jessica N. McAlpine, Ann Marie Swart, Gilles Freyer, Robert S. Mannel, Keiichi Fujiwara, Andres Poveda, Thigpen, T, Dubois, A, Mcalpine, J, Disaia, P, Fujiwara, K, Hoskins, W, Kristensen, G, Mannel, R, Markman, M, Pfisterer, J, Quinn, M, Reed, N, Swart, A, Berek, J, Colombo, N, Freyer, G, Gallardo, D, Plante, M, Poveda, A, Rubinstein, L, Bacon, M, Kitchener, H, and Stuart, G
- Subjects
Oncology ,medicine.medical_specialty ,Consensus ,Prognosi ,Endpoint Determination ,MED/40 - GINECOLOGIA E OSTETRICIA ,medicine.medical_treatment ,Alternative medicine ,MEDLINE ,law.invention ,First line therapy ,Gynecologic Surgical Procedures ,Randomized controlled trial ,Gynecologic Surgical Procedure ,law ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Medicine ,Humans ,Molecular Targeted Therapy ,Neoadjuvant therapy ,Gynecology ,Ovarian Neoplasms ,Chemotherapy ,Clinical Trials as Topic ,Antineoplastic Combined Chemotherapy Protocol ,business.industry ,Ovarian Neoplasm ,Carcinoma ,Obstetrics and Gynecology ,medicine.disease ,Prognosis ,Neoadjuvant Therapy ,Clinical trial ,Female ,business ,Ovarian cancer ,Human - Abstract
At the 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG) held in Vancouver, Canada, in June 2010, representatives of 23 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of large randomized trials. The process focused on 13 predetermined questions. Group A, 1 of the 3 discussion groups, addressed the first 5 questions, examining first-line therapies in newly diagnosed ovarian cancer patients.A1: What are the appropriate end points for different trials (maintenance, upfront chemotherapy trials including molecular drugs)?A2: Are there any subgroups defined by tumor biology who need specific treatment options/trials?A3: Is the 2004 GCIG-recommended standard comparator arm still valid?A4: What is the role of modifying dose, schedule, and delivery of chemotherapy?A5: What role does surgery play today?
- Published
- 2011
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.